Ascendis Pharma
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ASND and other ETFs, options, and stocks.About ASND
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs.
CEOJan Møller Mikkelsen
CEOJan Møller Mikkelsen
Employees—
Employees—
HeadquartersHellerup, Capital Region
HeadquartersHellerup, Capital Region
Founded2006
Founded2006
Employees—
Employees—
ASND Key Statistics
Market cap12.52B
Market cap12.52B
Price-Earnings ratio-42.01
Price-Earnings ratio-42.01
Dividend yield—
Dividend yield—
Average volume482.96K
Average volume482.96K
High today$212.48
High today$212.48
Low today$206.02
Low today$206.02
Open price$207.95
Open price$207.95
Volume256.56K
Volume256.56K
52 Week high$216.45
52 Week high$216.45
52 Week low$118.03
52 Week low$118.03
ASND News
TipRanks 2d
Ascendis Pharma price target raised to $254 from $203 at Cantor FitzgeraldCantor Fitzgerald analyst Li Watsek raised the firm’s price target on Ascendis Pharma (ASND) to $254 from $203 and keeps an Overweight rating on the shares. The...
Simply Wall St 5d
Ascendis Pharma Is Up 6.9% After EMA Filing for TransCon CNP in Achondroplasia TreatmentOn October 8, 2025, Ascendis Pharma A/S announced it had submitted a Marketing Authorisation Application to the European Medicines Agency for TransCon CNP (nave...
TipRanks 7d
Ascendis Pharma Submits EMA Application for Achondroplasia TreatmentElevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...
Analyst ratings
100%
of 15 ratingsBuy
100%
Hold
0%
Sell
0%
More ASND News
TipRanks 7d
Ascendis Pharma submits TransCon CNP marketing authorization application to EMAAscendis Pharma (ASND) announced it has submitted a marketing authorization application to the European Medicines Agency for TransCon CNP as a treatment for chi...